Quick Summary
Covering the latest research from top Wall Street investment banks

Novonesis Q1 Organic Growth Exceeds Expectations, Strong Performance in Food & Beverages Sector

Institution
Goldman Sachs
Date
20260505
Authors
Georgina Fraser, Ph.D., Gabriel Simoes, Marcus von Scheele, Thomas Ward
Company
Novonesis
Ticker
NSISB
Industry
European Chemicals
Rating
Buy
BullishHigh confidenceReiterateMedium-termMaintains Buy rating with target price Dkr475 implying 19.1% upside potential
AuthorsGeorgina Fraser, Ph.D., Gabriel Simoes, Marcus von Scheele, Thomas Ward
Target priceDkr475
CoverageEurope
Business segmentsFood & Beverages、Human Health、Household Care、Agriculture, Energy & Tech
Research firm divisions/subsidiariesGoldman Sachs International(Division/Team)

AI summary card

Novonesis Q1 Organic Growth Exceeds Expectations, Strong Performance in Food & Beverages Sector

Q1 2026 organic growth of 7% exceeded market expectations, with Food & Beverages sector growing 11% as the main driver, while profitability remained robust.

Buy|Target price Dkr475
Organic growthFood & BeveragesEBITDA marginEarnings beatBuy rating
  • 1Q26 organic growth of 7%, surpassing market expectations of 6.2%
  • Food & Beverages sector growth of 11%, significantly above expectations
  • Adjusted EBITDA margin of 37.8%, down 52bps year-on-year
  • Maintains full-year organic growth guidance of 5-7%
  • Target price Dkr475 implies 19.1% upside potential

Report interpretation

Overview

Goldman Sachs published its review of Novonesis' Q1 2026 earnings, noting that both organic growth and profitability exceeded expectations. The Food & Beverages sector performed particularly well, driving overall growth. Although some business segments fell short of expectations, the company maintained its full-year guidance, which could positively impact the stock price.

Core views

Growth: Q1 2026 organic growth of 7% was 80bps above the consensus expectation of 6.2%. The Food & Beverages sector grew 11%, significantly exceeding the expected 5.3%, driven by premiumization in dairy and cheese demand. Household Care grew 4%, above the expected 2.5%, benefiting from increased regional customer penetration. Human Health grew 5%, below the expected 8.1%, due to weak probiotic supplement demand in North America. Agriculture, Energy & Tech grew 5%, below the expected 8.7%, as plant and tech sales declined due to order timing. Profitability: Adjusted EBITDA margin was 37.8%, down slightly by 52bps year-on-year, as gross margin improvement and cost synergies were offset by higher operating expenses and currency headwinds. Food & Health Biosolutions margin was 35.7%, down 130bps; Planetary Health Biosolutions margin was 39.5%, up 10bps, benefiting from the consolidation of acquired feed enzyme operations. Outlook: Maintains FY26 organic growth guidance of 5-7%, including 1pp from pricing, 1pp from sales synergies, and approximately 1pp negative impact from exiting certain countries. Adjusted EBITDA margin is expected to be 37-38%, improving from 2025's 37.1%. The company sees no material impact from the Middle East conflict due to market diversification and regional production capabilities.

Analysis framework

Goldman Sachs employed a segment-by-segment analysis to assess growth drivers across business units, combined with organic growth breakdowns (e.g., impact of exiting countries, inventory buildup) to evaluate growth quality. Profitability analysis focused on gross margin, operating expenses, and currency impacts. Valuation used a two-stage DCF model, assuming a WACC of 7.1% and a terminal growth rate of 2.7%. The report compared consensus expectations with company guidance to assess the degree and sustainability of the earnings beat.

Methodology notes

  • Valuation MethodDCF

    Two-stage DCF model

    Calculates intrinsic value by forecasting future free cash flows and discounting to present value, assuming a WACC of 7.1% and a terminal growth rate of 2.7% to derive the target price.

  • Industry Analysis FrameworkVolume-Price Breakdown

    Organic growth breakdown

    Decomposes growth into price, volume, and M&A/divestiture impacts, noting 1pp from pricing, 1pp from synergies, and quantifying the negative impact from exiting countries.

  • Company Fundamentals & Financial FrameworkEarnings Quality Analysis

    Margin driver analysis

    Breaks down EBITDA margin changes into gross margin, operating expenses, and currency factors to assess earnings sustainability.

Key data

  • 1Q26 Organic Growth7%Above consensus of 6.2%
  • Food & Beverages Growth11%Above consensus of 5.3%
  • Adjusted EBITDA Margin37.8%Year-on-year -52bps
  • FY26 Organic Growth Guidance5-7%Unchanged
  • Target PriceDkr475Implies 19.1% upside

Impact & implications

The report suggests that the strong Food & Beverages performance and better-than-expected profitability will positively impact the stock price, despite some business segments falling short. The maintained full-year guidance and limited Middle East conflict impact bolster investor confidence. The stock has underperformed peers by 1% year-to-date, presenting a potential recovery opportunity post-earnings.

Risks

  • Post-acquisition integration issues may lead to higher-than-expected costs or slower growth
  • Significant delays in synergy realization
  • Weak Chinese consumption affecting Food & Beverages
  • Lower oil prices reducing enzyme substitution appeal
  • Slowing dietary supplement demand or increased competition impacting Human Health
  • Weak animal nutrition demand dragging Agriculture, Energy & Tech

What to watch

  • Improvement in plant and tech order timing
  • Energy business run-rate and Middle East conflict impact
  • Sustainability of Food & Beverages growth
  • Progress in synergy realization
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins